• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Pathophysiological role of mast cells in cardiovascular diseases.

Research Project

Project/Area Number 16590193
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field General pharmacology
Research InstitutionShimane University

Principal Investigator

SHIOTA Naotaka  Shimane University, School of medicine, associate professor, 医学部, 助教授 (60206050)

Co-Investigator(Kenkyū-buntansha) TANAKA Tetsuya  Shimane University, School of medicine, assistant professor, 医学部, 助手 (10346380)
Project Period (FY) 2004 – 2005
Project Status Completed (Fiscal Year 2005)
Budget Amount *help
¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 2005: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2004: ¥1,400,000 (Direct Cost: ¥1,400,000)
Keywordsmast cell / chymase / fibrosis / cardiovascular disease
Research Abstract

1 Mast cells are multi-potent inflammatory cells, which express numerous bioactive factors, such as cytokines, growth factors, and proteases. Mast cells are known to locate in cardiovascular tissues. However, the role of mast cells on the pathogenesis of cardiovascular disease is unknown.
2 Our present study attempted to clarify the role of mast cells by analyzing spontaneously hypertensive rats (SHR), which is known to develop genetically hypertension, cardiac hypertrophy, and heart failure.
3 Histochemical analysis revealed that the number of mast cells in the cardiovascular tissues of prehypertensive (2 weeks-old) SHR was significantly higher than that of normal control WKY rats, and mast cells are one of the major cells producing TNF-alpha and chymase. Furthermore, TNF-alpha,NF-kB,IL-6,SCF and c-kit mRNA levels in the cardiovascular tissues in SHR were higher than those in WKY rats.
4 To further investigate the role of mast cells in SHR, we evaluated the therapeutic effects of a mast cell stabilizer, tranilast, on the development of hypertension in SHR. Montelukast (300 mg/kg/day) was orally administered to SHR for 10 weeks, starting at the age of 2 weeks.
5 Treatment with tranilast significantly inhibit the development of hypertension, and decreased the number of mast cells in cardiovascular tissues in SHR. Tranilast also suppressed the perivascular fibrosis and vascular thickening.
6 In conclusion, our results support the hypothesis that activation of mast cells in cardiovascular tissues may play a key role in the pathogenesis of cardiovascular diseases.

Report

(3 results)
  • 2005 Annual Research Report   Final Research Report Summary
  • 2004 Annual Research Report
  • Research Products

    (3 results)

All 2005 Other

All Journal Article (3 results)

  • [Journal Article] Effect of mast cell chymase inhibitor on the development of scleroderma in tight skin mice2005

    • Author(s)
      Naotaka Shiota
    • Journal Title

      British Journal of Pharmacology 145・4

      Pages: 424-431

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice.2005

    • Author(s)
      Shiota N., Kakizoe E., Shimoura K., Tanaka T., Okunishi H.
    • Journal Title

      British Journal of Pharmacology 145(5)

      Pages: 424-431

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Effect of mast cell chymase inhibitor on the development of scleroderma in tight skin mice.

    • Author(s)
      Naotaka Shiota
    • Journal Title

      British Journal of Pharmacology (発表予定)

    • Related Report
      2004 Annual Research Report

URL: 

Published: 2004-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi